Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51,865 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Kim K, et al. Cancer. 2021 Oct 15;127(20):3772-3781. doi: 10.1002/cncr.33689. Epub 2021 Jul 13. Cancer. 2021. PMID: 34255353 Free PMC article.
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Kim K, et al. Am J Hematol. 2022 Jul;97(7):885-894. doi: 10.1002/ajh.26572. Epub 2022 Apr 29. Am J Hematol. 2022. PMID: 35413152 Free article.
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Rivera D, et al. Among authors: kim k. Am J Hematol. 2022 Dec;97(12):1599-1606. doi: 10.1002/ajh.26731. Epub 2022 Oct 19. Am J Hematol. 2022. PMID: 36117258 Free article.
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Chien KS, et al. Among authors: kim k. Br J Haematol. 2021 Nov;195(3):378-387. doi: 10.1111/bjh.17689. Epub 2021 Aug 2. Br J Haematol. 2021. PMID: 34340254 Clinical Trial.
51,865 results
You have reached the last available page of results. Please see the User Guide for more information.